While PD-L1/PD-1, microsatellite instability (MSI), tumor mutational burden (TMB), and aminoacyl tRNA synthetase complex interacting with multifunctional protein 2 (AIMP2) are well-established biomarkers, their clinical application remains limited [15, 16], highlighting the urgent need to identify alternative markers. This evidence concerns the gene AIMP2 and neoplasm.